Although previous clinical trials have shown that GIST patients with KIT exon 11 mutations may obtain more benefits from adjuvant imatinib therapy (Corless et al., 2014; Joensuu et al., 2017), more detailed analyses should be considered to evaluate the functional and clinical roles of different mutation types of exon 11. Here, KIT is linked to gastrointestinal stromal tumor.